@bubu12

c’est encore plus détaillé dans le rapport de l’EMA...

Alors, le rapport de la FDA ne fait pas référence au b1, effectivement... Je l’admets, enfin quoique.

Par contre, celui de l’EMA, oui... Et c’est très beau !

b1 et b2, c’est la même chose. Vas y que je te mélange les résultats !
Enfin presque parce que devinez quoi :

b2 evaluating is "ongoing" !!!

"Clinical aspects2.4.1.
Introduction
Pfizer and BioNTech have developed a vaccine that targets SARS-CoV-2, intended to prevent COVID-19, for which BioNTech initiated a FIH study in April 2020 in Germany (BNT162-01) and Pfizer initiated a Phase 1/2/3 study (C4591001) shortly afterwards in the US which expanded to include global sites upon initiation of the Phase 2/3 part of the study.

Phase 1/2 Study BNT162-01
Study BNT162-01 is the ongoing, FIH, Phase 1 dose level-finding study, in which healthy adults 18 to 55 years of age all receive active vaccine. This study is evaluating the safety and immunogenicity of several different candidate vaccines at various dose levels. The protocol was later amended to allow inclusion of older adult participants up to 85 years of age. The available Phase 1 safety and immunogenicity data for adults 18 to 55 years of age are reported in this application. Multiple vaccine candidates are being evaluated in this study. For each vaccine candidate, participants received escalating dose levels (N=12 per dose level) with progression to subsequent dose levels based on recommendation from a Sponsor Safety Review Committee (SRC).

Phase 1/2/3 Study C4591001
Study C4591001 is the ongoing,..."

Etc...
..
.

MERDEEEE...

Bon, je vous laisse lire le doc au cas ou.

Traduction de "ongoing" : en cours...
Et de "planned" : planifié (donc, plus tard !).

On ne sait jamais... Peut être que certaines personnes ont du mal avec l’Anglais.

Et au passage ça :
Nonclinical evaluation of BNT162b2 included pharmacology (mouse immunogenicity and nonhuman primate [NHP] immunogenicity and SARS-Cov-2 challenge studies), pharmacokinetic (series of biodistribution, metabolism and pharmacokinetic studies), and toxicity (2 Good Laboratory Practice [GLP] rat repeat-dose toxicity) studies in vitro and in vivo.

Ça veut juste dire qui savent ce que c’est. C’est déjà ça vous me direz. Aucune mention d’un quelconque résultat ! C’est trop beau...